125 Participants NeededMy employer runs this trial

Peanut Consumption for Fatty Liver

MT
Overseen ByMenghua Tao, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Henry Ford Health System
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines whether eating peanuts can benefit individuals with metabolic associated fatty liver. Researchers aim to determine if peanuts can improve liver health, influence metabolism, and alter gut bacteria. Participants will either consume peanuts daily or maintain their usual diet for 12 weeks. Ideal candidates are those diagnosed with metabolic associated fatty liver who rarely consume peanuts or tree nuts and can read and understand English. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that may lead to new dietary recommendations for liver health.

Is there any evidence suggesting that peanut consumption is safe for patients with metabolic associated fatty liver?

Research suggests that eating peanuts might be safe for people with fatty liver. Studies have found that peanuts, especially those high in oleic acid, could help reduce fatty liver symptoms, potentially improving liver health in some cases.

However, peanuts carry a small risk of contamination with aflatoxin, a harmful substance that can cause liver issues. Although rare, this risk should be considered when consuming peanuts. Overall, peanuts appear well-tolerated, but it's important to eat them in moderation and ensure they come from a safe source.12345

Why are researchers excited about this trial?

Most treatments for fatty liver disease focus on lifestyle changes like weight loss and exercise or medications that manage symptoms. But peanut consumption offers a novel approach by potentially leveraging the nutritional benefits of peanuts, such as healthy fats and antioxidants, which may directly impact liver health. Researchers are excited because incorporating peanuts is a simple dietary change that could improve liver function and overall health without the need for medications. This approach might provide an accessible, natural option for managing fatty liver disease.

What evidence suggests that peanut consumption might be an effective treatment for fatty liver?

This trial will evaluate the effects of peanut consumption on fatty liver. Studies have shown that regularly eating nuts, including peanuts, can improve fat processing, control blood sugar levels, and support weight loss—all crucial for managing fatty liver. Research indicates that men who ate the most nuts had a 57% lower risk of developing non-alcoholic fatty liver disease (NAFLD) compared to those who ate fewer nuts. Peanuts, high in oleic acid, may help delay fatty liver symptoms. Observational studies also suggest that moderate peanut consumption links to a lower chance of NAFLD and better overall health. These findings suggest that eating peanuts might improve liver health in people with fatty liver disease. Participants in this trial will consume 50 grams of peanuts daily for 12 weeks to assess these potential benefits.12345

Are You a Good Fit for This Trial?

This trial is for adults aged 30-70 who have early-stage metabolic associated fatty liver disease, rarely eat peanuts or similar foods, can speak and read English, and are able to give consent.

Inclusion Criteria

I am between 30 and 70 years old.
Do not consume peanut, peanut butter, treenuts, or seeds more than once per week
Able to understand, speak, and read English
See 2 more

Exclusion Criteria

Food allergy to peanuts or peanut-containing products
Alcohol use disorder as determined by AUDIT screening
I have been diagnosed with lymphoma.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. Stool sample and blood collection at baseline and post-intervention. Daily log for tracking peanut consumption. 2-day Dietary recall at baseline, during Week 6 and Week 12.

12 weeks
Baseline, Week 6, Week 12 (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including post-intervention Fibro scans for participants with baseline scans available.

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Peanut consumption

Trial Overview

The study tests if eating peanuts daily for 12 weeks improves liver health and metabolism in people with fatty liver disease. Participants are randomly assigned to either a peanut-eating group or a regular diet group.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: PeanutExperimental Treatment1 Intervention
Group II: ControlActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Henry Ford Health System

Lead Sponsor

Trials
334
Recruited
2,197,000+

Citations

Nuts and Non-Alcoholic Fatty Liver Disease - PMC - NIH

In summary, regular nut intake induces an amelioration in lipid metabolism, may help glycemic control and helps weight reduction; all effects which are main ...

High oleic peanuts improve parameters leading to fatty ...

These findings suggest that consumption of peanuts high in oleic acid (D7) may have the potential to delay primary fatty liver symptoms.

Effects of Peanut Consumption on Adults With Metabolic ...

The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. alter the gut ...

Association between nut intake and non-alcoholic fatty liver ...

Key Findings: For men who ate the highest amount of nuts (including peanuts), nut consumption was associated with a 57% reduced risk of NAFLD compared with men ...

Are Peanuts Good for Fatty Liver? Evidence and Guidance

Observational studies suggest moderate nut consumption, including peanuts, is associated with lower NAFLD prevalence and improved metabolic ...